David A. Dodd Acquires 10,000 Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) Stock

GeoVax Labs, Inc. (NASDAQ:GOVX) CEO David A. Dodd purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The stock was acquired at an average cost of $1.08 per share, with a total value of $10,800.00. Following the purchase, the chief executive officer now owns 36,661 shares of the company’s stock, valued at approximately $39,593.88. This represents a 37.51 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

GeoVax Labs Stock Up 9.3 %

Shares of GOVX stock opened at $1.18 on Thursday. The stock has a 50-day simple moving average of $1.60 and a 200 day simple moving average of $2.09. The stock has a market capitalization of $11.13 million, a P/E ratio of -0.21 and a beta of 3.06. GeoVax Labs, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $2.38 million. On average, sell-side analysts anticipate that GeoVax Labs, Inc. will post -4.49 earnings per share for the current year.

Analysts Set New Price Targets

Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a research note on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and a consensus target price of $14.20.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the fourth quarter worth $104,000. Virtu Financial LLC acquired a new stake in GeoVax Labs during the 3rd quarter worth about $97,000. Finally, Northern Trust Corp acquired a new stake in shares of GeoVax Labs during the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.